Sagent Pharmaceuticals, which markets generic injectable drugs to hospitals, raised $92 million by offering 5.8 million shares (15% more than originally planned) at $16, at high end of the range of $14 to $16. Sagent Pharmaceuticals plans to list on the NASDAQ under the symbol SGNT. Morgan Stanley, BofA Merrill Lynch and Jefferies & Co. acted as lead managers on the deal.
